Sempra Energy vs Viatris Inc — how do they compare? Sempra Energy trades at $80.49 (market cap $52.36B), while Viatris Inc trades at $17.38 (market cap $20.03B). The key difference: Sempra Energy is far larger — about 2.6× Viatris Inc's market cap, and Sempra Energy pays the higher dividend (3.28%). Which is the better fit depends on your goals — on Pluang, investors hold Sempra Energy for 8 Days and Viatris Inc for 57 Days on average.
| SRE | VTRS | |
|---|---|---|
Market Cap | $52.36B | $20.03B |
Volume | 3,338,383 | 14,109,977 |
Sector | Utilities | Health |
52-Week High | $99.75 | $18.27 |
52-Week Low | $76.90 | $9.74 |
Typical Hold Time | 8 Days | 57 Days |
Enterprise Value | $89.00B | $32.15B |
Dividend Yield | 3.28% | 2.75% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Viatris (VTRS) trades at $17.49, down 0.29% with a bullish technical signal supported by moving averages and oversold RSI levels. The company shows consistent earnings beats with Q2 2026 EPS of $0.69 exceeding expectations, while maintaining strong operational cash flow of $2.32B in 2025. Recent developments include FDA approval for WAKIX in Japan and continued recognition as a top employer.
Despite negative net margins, Viatris demonstrates improving cash flow trends and strategic portfolio optimization. The stock offers 27% upside to consensus price target of $22.17, though investors face risks from debt levels and competitive pressures in the generic drug market. Deleveraging progress and pipeline advancements support potential re-rating.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Sempra is an energy infrastructure company with regulated utility and energy network businesses. Its operations include electric and gas utilities as well as energy infrastructure in North America.
Read more on SRE →Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →